Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Impact of Venous Thromboembolism In Critically Ill Patients: A Meta-Analysis of Major Clinical outcomes

Alessandra Malato, MD, PhD, Francesco Dentali, MD, Francesco Fabbiano, MD, Giorgia Saccullo, MD, Vincenzo Abbadessa, MD, Sergio Siragusa, MD

Blood (2010) 116 (21): 3327.

https://doi.org/10.1182/blood.V116.21.3327.3327

Published: 2010

Journal Articles

BCR-ABL IS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.

Paolo Vigneri, MD, PhD, Fabio Stagno, MD, Stefania Stella, PhD, Alessandra Cupri, MD, PhD, Michele Massimino, PhD, Agostino Antolino, MD, Vincenzo Abbadessa, MD, Maura Brugiatelli, MD, Patrizia Guglielmo, MD, Caterina Musolino, MD, Diamante Turri, MD, Mario Russo, MD, Guido Pagnucco, MD, Michele Rizzo, MD, Maurizio Musso, MD, Fortunato Morabito, MD, Luciano Levato, Angelo Messina, MD, Francesco Di Raimondo, MD

Blood (2010) 116 (21): 3426.

https://doi.org/10.1182/blood.V116.21.3426.3426

Published: 2010

Journal Articles

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.

Blood (2009) 114 (22): 4276.

https://doi.org/10.1182/blood.V114.22.4276.4276

Published: 2009

Journal Articles

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

Gerlando Quintini, MD, Domenica Caramazza, MD, Vincenzo Barbera, MD, Silvana Maisano, MD, Vincenzo Spadola, Ph.D, Sergio Siragusa, MD, Vincenzo Abbadessa, MD

Blood (2007) 110 (11): 4354.

https://doi.org/10.1182/blood.V110.11.4354.4354

Published: 2007

Journal Articles

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Emilio Iannitto, MD, Viviana Minardi, MD, Antonino Mulè, MD, Renato Scalone, MD, Giuseppina Calvaruso, MD, Alessandra Crescimanno, MD, Concetta Lo Biundo, MD, Eliana Liardo, MD, Vincenzo Abbadessa, MD, Maurizio Musso, MD, Serenella Arista, MD

Blood (2006) 108 (11): 5286.

https://doi.org/10.1182/blood.V108.11.5286.5286

Published: 2006

Journal Articles

Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.

Emilio Iannitto, MD, Viviana Minardi, MD, Paolo G. Gobbi, MD, Giuseppina Calvaruso, MD, Caterina Stelitano, MD, Luca Baldini, MD, Francesco Merli, MD, Mario Petrini, MD, Luigi Marcheselli, Ph.D, Caterina Mammi, Ph.D, Stefano De Cantis, MD, Vincenzo Abbadessa, MD, Massimo Federico, MD

Blood (2006) 108 (11): 2475.

https://doi.org/10.1182/blood.V108.11.2475.2475

Published: 2006

Journal Articles

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Emilio Iannitto, MD, Viviana Minardi, MD, Giuseppina Calvaruso, MD, Antonino Mulè, MD, Donatella Ferraro, PhD, Emanuele Ammatuna, MD, Antonio Craxì, MD, Vincenzo Abbadessa, MD, Rosellina Di Stefano

Blood (2004) 104 (11): 4816.

https://doi.org/10.1182/blood.V104.11.4816.4816

Published: 2004

NARROW

The Impact of Venous Thromboembolism In Critically Ill Patients: A Meta-Analysis of Major Clinical outcomes

BCR-ABL IS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Email alerts

ASH Publications

American Society of Hematology

The Impact of Venous Thromboembolism In Critically Ill Patients: A Meta-Analysis of Major Clinical outcomes

BCR-ABL IS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only